Ticagrelor for the primary prevention of stroke in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials
In conclusion, available evidence from aggregate data supported a modest advantage of ticagrelor-involving regimens for the primary stroke prevention in CAD compared with other antiplatelet regimens after the trade-off between reducing IS and inducing ICH, where more benefits might be expected from long-term and low-dose use of tica grelor among patients with chronic coronary syndrome. Further collaborative meta-analysis of individual participant data from well-designed and statistically-powered trials would be needed to generate high quality evidence on this issue.
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
More News: Clinical Trials | Hematology | Hemorrhagic Stroke | Ischemic Stroke | Science | Statistics | Stroke | Thrombosis